Can a new antibody tame the Body's allergic alarm system?

NCT ID NCT07757659

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called XKH001 in healthy Caucasian adults. The drug is an antibody designed to block a protein involved in allergic and inflammatory responses. The study aims to see how the body processes the drug, whether it is safe and well-tolerated, and how it compares to earlier results in Chinese participants. It is a small, placebo-controlled study, meaning some participants will receive the drug and others will receive an inactive injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
XKH001, an experimental antibody that targets a protein called IL-25, given as an injection
What this could lead to
If successful, this could support the development of XKH001 as a potential treatment for conditions involving IL-25, such as allergic or inflammatory diseases.
What could go wrong
This is a very early, small study focused on safety and drug processing, not on treating any disease. The drug may not prove effective or safe in later, larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Q-Pharm Pty Limited (also known as Nucleus Network Brisbane)

    Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.